Parkinson's disease improved function with GM1 ganglioside treatment in a randomized placebo-controlled study

Neurology

Volumn 50, Issue 6, 1998, Pages 1630-1636

  Schneider, J S ^a   Roeltgen, D P ^d   Mancall, E L ^b   Chapas Crilly, J ^a   Rothblat, D S ^a   Tatarian, G T ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d Hlth Educ Res Found W   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031798568     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.6.1630     Document Type: Article

References (46)

1. Montgomery EB Jr. Pharmacokinetics and pharmacodynamics of levodopa. Neurology 1992;42(suppl 1):17-22.
2. Koller WC, Hubble JP. Levodopa therapy in Parkinson's disease. Neurology 1990;40(suppl 3):40-47.
3. Melamed E. Mechanisms of action of exogenous L-dopa. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore, MD: Urban and Schwarzenberg, 1988: 87-94.
4. Wu G, Lu Z-H, Ledeen RW. Induced and spontaneous neuritogenesis are associated with enhanced expression of ganglioside GM1 in the nuclear membrane. J Neurosci 1995;15:3739-3746.
5. Ledeen RW. Biology of gangliosides: neuritogenic and neuronotrophic properties. J Neurosci Res 1984;12:147-159.
6. Skaper SD, Leon A, Toffano G. Ganglioside function in the development and repair of the nervous system. Mol Neurobiol 1989;3:173-199.
7. Fishman PH. Gangliosides as cell surface receptors and transducers of biological signals. In: Ledeen RW, Hogan EL, Tettamanti G, et al., eds. New trends in ganglioside research: neurochemical and neuroregenerative aspects. Padova: Liviana Press, 1988:183-202.
8. Dawson G, Vartanian T. Glycolipids as the source and modulator or receptor-mediated second messengers. In: Ledeen RW, Hogan EL, Tettamanti G, et al., eds. New trends in ganglioside research: neurochemical and neuroregenerative aspects. Padova: Liviana Press, 1988:219-228.
9. Ramirez JJ, Sabel BA. Toward a unified theory of ganglioside-mediated functional restoration after brain injury: lesion size, not lesion site, is the primary factor determining efficacy. Acta Neurobiol Exp 1990;50:415-438.
10. Cuello AC. Glycosphingolipids that can regulate nerve growth and repair. Adv Pharmacol 1990;21:1-49.
11. Gorio A, Carmignoto G, Finesso M, Polato P, Nunzi MG. Muscle reinnervation. II. Sprouting, synapse formation and regression. Neuroscience 1983;8:403-416.
12. Hadjiconstantinou M, Rossetti EL, Paxton RC, Neff NH. Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP. Mol Pharmacol 1986;25:1075-1077.
13. Schneider JS, Yuwiler A. GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in a mouse model of MPTP-induced parkinsonism. Exp Neurol 1989;105: 177-183.
14. Schneider JS. Effects of age on GM1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. Neuropharmacology 1992;31:185-192.
15. Hadjiconstantinou M, Mariani AP, Neff NH. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study. Brain Res 1989;484: 297-303.
16. Stull ND, Schneider JS, Iacovitti L. GM1 ganglioside partially rescues cultured dopaminergic neurons from MPP-induced damage: dependence on initial damage and time of treatment. Brain Res 1994;640:308-315.
17. Schneider JS, Pope A, Simpson K, Taggart J, Smith MG, DiStefano L. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 1992;256: 843-846.
18. Herrero MT, Perez-Otano I, Oset C, et al. GM1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. Neuroscience 1993;56: 965-972.
19. Coleman A, Roeltgen DP, Schneider JS. Chronic GM1 ganglioside administration reverses cognitive deficits and delays onset of motor symptoms in a slowly progressing Parkinson model in monkeys. Soc Neurosci Abstr 1994;20:1646. Abstract.
20. Schneider JS, Pope-Coleman A. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 1995;4:245-255.
21. Schneider JS, Roeltgen DP, Rothblat DS, Chapas-Crilly J, Seraydarian L, Rao J. GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy. Neurology 1995;45:1149-1154.
22. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
23. Fahn S, Elton RL, the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease. Vol 2. Florham Park, NJ: Macmillan Health Care Information, 1987:153-164.
24. Schneider JS, Diamond SG, Markham CH. Parkinson's disease: sensory and motor problems in arms and hands. Neurology 1987;37:951-956.
25. Vingerhoets FJG, Schulzer M, Calne DB, Snow BJ. Which clinical signs of Parkinson's disease best reflect the nigrostriatal lesion? Ann Neurol 1997;41:58-64.
26. Roberts JW, Hoeg JM, Mouradian MM, Linfante I, Chase TN. Iatrogenic hyperlipidaemia with GM1 ganglioside. Lancet 1993;342:115.
27. Figueras A, Morales-Olivas FJ, Capella D, Palop V, Laporte JR. Bovine gangliosides in acute polyneuropathy. BMJ 1992; 305:1330-1331.
28. Landi G, D'Alessandro R, Dossi BC. Guillain-Barré syndrome after exposure to gangliosides. BMJ 1993;307:1463-1464.
29. Raschetti R, Maggini M, Popoli P, et al. Gangliosides and Guillain-Barré syndrome. J Clin Epidemiol 1995;48:1399-1405.
30. Granieri E, Casetta I, Govoni V, Tola MR, Paolino E, Rocca WA. Ganglioside therapy and Guillain-Barré syndrome: a historical cohort study in Ferrara, Italy fails to demonstrate an association. Neuroepidemiology 1991;10:161-169.
31. Granieri E, Casetta I, Govoni V, Tola MR, Paolino E, Rocca WA. Incidence of Guillain-Barré syndrome in Ferrara, northern Italy, 1981-1987. Neuroepidemiology 1991;10:105-111.
32. Matias-Guiu J, Martin R, Blanquer J, et al. The incidence of Guillain-Barré syndrome and ganglioside intake in Alcoi Spain. Neuroepidemiology 1993;12:58-60.
33. Yu RK, Saito RK, Zhang Y, Fiorentini R, Khin-Maung-Gyi F, Friday GH. Analysis of serum anti-GM1 antibody titers in patients receiving GM1 therapy. Soc Neurosci Abstr 1992;18: 1472. Abstract.
34. Ala TA, Perfetti PA, Frey WH II. Two cases of acute anti-GM1 antibody elevations in response to exogenous GM1 without neurologic symptoms. J Neuroimmunol 1994;53:109-113.
35. Bellato P, Milan F, Toffano G. Disposition of exogenous titium-labeled GM1 monosialoganglioside in the rat. Clin Trial J 1989;26:39-48.
36. Tettamanti G, Venerando B, Roberti S, Chigorno V, Sonnino S, Ghidoni R. The fate of exogenously administered brain gangliosides. In: Rapport MM, Gorio A, eds. Gangliosides in neurological and neuromuscular function. Development and repair. New York: Raven Press, 1981:225-240.
37. Schneider JS, Kean A, DiStefano L. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. J Neurosci Res 1995;42:117-123.
38. Herrero MT, Kastner A, Perez-Otano I, et al. Gangliosides and parkinsonism. Neurology 1993;43:2132-2134.
39. Maysinger D, Herrera-Marschitz M, Ungerstedt U, Cuello AC. Acetylcholine release in vivo: effects of chronic treatment with monosialoganglioside GM1. Neuropharmacology 1990;29:151-159.
40. Aldinio C, Valenti G, Savoini GE, Kirschner G, Agnati LF, Toffano G. Monosialoganglioside internal ester stimulates the dopaminergic reinnervation of the striatum after unilateral hemitransection in rat. Int J Dev Neurosci 1984;2:267-275.
41. Schneider JS, DiStefano L. Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments. Brain Res 1995;674:260-264.
42. Fadda E, Negro A, Facci L, Skaper SD. Ganglioside GM1 cooperates with brain derived neurotrophic factor to protect dopaminergic neurons from 6-hydroxydopamine-induced degeneration. Neurosci Lett 1993;159:147-150.
43. Ferrari G, Anderson BL, Stephens RM, Kaplan DR, Greene LA. Prevention of apoptotic neuronal death by GM1 ganglioside. J Biol Chem 1995;270:3074-3080.
44. Skaper SD, Negro A, Dal Toso R, Facci L. Recombinant human ciliary neurotrophic factor alters the threshold of hippocampal pyramidal neuron sensitivity to excitotoxin damage: synergistic effects of monosialogangliosides. J Neurosci Res 1992;33:330-337.
45. Ferrari G, Batistatou A, Greene LA. Gangliosides rescue neuronal cells from death after trophic factor deprivation. J Neurosci 1993;13:1879-1887.
46. McGeer PL, Itagaki S, Akiyam H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological processes. Ann Neurol 1988;24:574-576.